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The prevalence of toxigenic Clostridium difficile in Korea has been reported to be approximately
60–80%. Although the prevalence of the tcdA”tcdB+ C. difficile strain was less then 5% prior to
the year 2000, it has become an emerging nosocomial pathogen in Korea. Therefore, we have
attempted to determine the multicentre nationwide prevalence of tcdA+tcdB+ and tcdA”tcdB+
C. difficile for epidemiological purposes. C. difficile strains (n5724, 30 from 2000, 80 from 2001,
74 from 2002, 76 from 2003, 179 from 2004, 285 from 2005) were obtained retrospectively from
January 2000 to December 2005 from in-patients at 6 hospitals, all of whom were suspected of
having C. difficile-associated disease (CDAD), colitis or pseudomembranous colitis. The numbers
of participating hospitals varied yearly (1 in 2000, 2 in 2001–2003, 3 in 2004, 5 in 2005). The
hospitals were located in Seoul (n54), Kyunggi Province (n51) and Busan (n51), Korea. PCR
assays for tcdA and tcdB genes were conducted using 724 unduplicated C. difficile isolates. The
mean prevalence of tcdA+tcdB+ and tcdA”tcdB+ C. difficile strains over the 6 years was 51.8%
(38.4–59.3%) and 25.8%(10–56.0%), respectively. The mean prevalence of tcdA”tcdB+ C.
difficile strains was less than 7% until 2002, but began to increase in 2003 (13.2%) and
achieved a peak in 2004 (50.3%). In 2005, the mean prevalence of tcdA+tcdB+ and
tcdA”tcdB+ C. difficile strains was 47.7% (30.9–60.3%) and 27.0% (17.6–54.8%),
respectively. This nationwide epidemiological study showed that tcdA”tcdB+ C. difficile strains
have already spread extensively throughout Korea, and our results provide basic data regarding
the controversies currently surrounding the toxigenicity of tcdA”tcdB+ C. difficile. The use of
enzyme immunoassays capable of detecting both TcdA and TcdB is strongly recommended for
the diagnosis of CDAD in microbiology laboratories, in order to control the spread of the
tcdA”tcdB+ strains of C. difficile.
INTRODUCTION
Clostridium difficile is one of the most common nosoco-
mial pathogens and is responsible for C. difficile-associated
disease (CDAD) and pseudomembranous colitis (PMC). C.
difficile can be either toxigenic or non-toxigenic. Toxigenic
C. difficile strains generally produce an enterotoxin (TcdA)
and a cytotoxin (TcdB). These toxins are encoded by two
genes, tcdA and tcdB, which have been mapped to a 19.6 kb
chromosomal pathogenicity locus (PaLoc) (Rupnik et al.,
1998). Besides both of these genes, three additional
Abbreviations: CDAD, Clostridium difficile-associated disease; EIA,
enzyme immunoassay; PaLoc, pathogenicity locus; PMC, pseudomem-
branous colitis.
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regulatory genes (tcdC, tcdD and tcdE) are located within
the PaLoc (Braun et al., 1996; Hammond & Johnson, 1995;
Cohen et al., 2000). However, a number of different genetic
variants of C. difficile have been reported with increasing
frequency worldwide. C. difficile strains with various
genetic modifications within the PaLoc have been studied
in the past, and 28 different toxinotypes have been
identified (Rupnik et al., 1998). These include variants of
C. difficile that harbour deletions, insertions or poly-
morphic restriction sites in one or more of the genes within
the PaLoc, but still generate functional TcdA and TcdB
toxins (TcdA+TcdB+ strains). However, strains of tox-
inotypes VIII, X, XVI and XVII generate a functional TcdB
but no TcdA (TcdA2TcdB+ strains), whereas strains
grouped into toxinotype XI harbour only the 39 portion
of tcdA and generate neither TcdA nor TcdB
(TcdA2TcdB2strains) (Von Eichel-Streiber et al., 1999;
Rupnik et al., 1997; Rupnik, 2001). Until recently, it was
believed that all C. difficile strains responsible for diseases
generated both TcdA and TcdB, which functioned
synergistically. However, a great many recent studies have
shown that TcdA2TcdB+ strains are involved in a wide
spectrum of CDAD ranging from colonization, to uncom-
plicated diarrhoea to PMC (Brazier et al., 1999; Al-Barrak
et al., 1999; Alfa et al., 2000; Limaye et al., 2000; Johnson et
al., 2001; Kuijper et al., 2001; Pituch et al., 2001).
The prevalence rates of these TcdA2TcdB+ strains were
reported as ranging from 0.2 to 56% in different studies
from the USA, Europe and Asia (Kato et al., 1998; Lyerly
et al., 1998; Pituch et al., 2001; Barbut et al., 2002; Samra
et al., 2002; Rupnik et al., 2003; Geric et al., 2004).
However, as the TcdA2TcdB+ C. difficile prevalence rate
has been reported to be as high as 39% in one Japanese
study (Komatsu et al., 2003) and a highly prevalent
TcdA2TcdB+ C. difficile strain was detected in a tertiary
hospital in Korea, this variant strain has become recog-
nized as an emerging pathogen in Korea (Shin & Kuak,
2006; Shin et al., 2008). Therefore, it is important to
determine at what time the TcdA2TcdB+ C. difficile strains
became prevalent and when they really began to be widely
distributed throughout Korea. In this study, we have
investigated the nationwide prevalence of TcdA+TcdB+
and TcdA2TcdB+ C. difficile strains in Korea from 2000 to
2005 for epidemiological purposes.
METHODS
Specimens. A total of 724 strains of C. difficile (30 from 2000, 80
from 2001, 74 from 2002, 76 from 2003, 179 from 2004, 285 from
2006) were obtained between January 2000 and December 2005 from
in-patients at 6 hospitals suspected of harbouring CDAD, colitis or
PMC. The numbers of participating hospitals varied yearly (1 in 2000,
2 in 2001–2003, 3 in 2004, 5 in 2005). The hospitals were located in
Seoul (n54), Kyunggi Province (n51) and Busan (n51), Korea, and
the mean number of beds was 920, with a range of 400–2000 (Fig. 1).
C. difficile cultures. Stool samples collected from patients suspected
to be infected with C. difficile were inoculated into anaerobically
reduced cycloserine–cefoxitin–fructose agar at 37 uC under anaerobic
conditions for 48–72 h in each participating hospital. The identifica-
tion of C. difficile was conducted in each participating laboratory in
accordance with local techniques, which included analysis of Gram
stain, spore stain, characteristic odour and typical morphological
features, and/or enzyme immunoassays (EIAs) to detect TcdA.
Isolates sent to the central coordinating laboratory were then
subcultured, and identification was confirmed via a biochemical
assay using an ANA identification test kit (bioMe´rieux).
PCR assay for tcdA and tcdB. Genes that encode the large
clostridial toxins A and B (tcdA and tcdB) were detected by PCR in
accordance with the methods described by Kato et al. (1998), with
some modifications, on 724 strains of C. difficile. Template DNA was
prepared by suspending 20 colonies in a 5% (w/v) solution of Chelex-
100 (Bio-Rad), boiling for 12 min, then centrifuging for 5 min at
12 000 g. The total volume of the PCR reaction was 100 ml, and it
contained ~30 ng bacterial DNA preparation, 0.15 mg each primer,
the four dNTPs (200 mM each), 10 mM Tris/HCl (pH 8.3), 2.5 mM
MgCl2, 50 mM KCl and 2.5 U Taq polymerase. tcdA and tcdB were
amplified using the following primers: NK9 (59-CCACCA
GCTGCAGCCATA-39) and NK11 (59-TGATGCTAATAATGAA
TCTAAAATGGTAAC-39), which were derived from the repeating
sequence of tcdA; and primers NK104 (59-GTGTAGCAATGAAA
GTCCAAGTTTACGC-39) and NK105 (59-CACTTAGCTCTTT
GATTGCTGCACCT-39), which were derived from the non-repeating
sequence of tcdB, respectively. The ATCC 43596 strain (serogroup C)
was utilized as the tcdA+tcdB+ control and ATCC 43598 strain
(serogroup F) was used as the tcdA2tcdB+ variant control. PCR
amplification using NK9/NK11 was conducted in a thermal cycler
(Perkin-Elmer) with 40 cycles of 95 uC for 15 s, 62 uC for 120 s and
72 uC for 40 s. For the primer pairs NK104/NK105 as the following
thermal profile was used: 40 cycles at 95 uC for 20 s, 62 uC for 60 s
and 74 uC for 40 s. At the conclusion of these PCR cycles, the tubes
were incubated for 5 min at 74 uC. Following completion of the
PCRs, 10 ml amplified product was electrophoresed in 2% agarose gel
and the bands were visualized by UV transillumination.
Strains in which the tcdA gene was intact yielded 1200 bp PCR
products, and tcdA2tcdB+ variant strains, yielded 700 or 500 bp
PCR products. In C. difficile strains with an intact tcdB+ gene, the
PCR product for tcdB was 204 bp.
Fig. 1. The location and number of beds for each of the six
participating hospitals.
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RESULTS
The total number of C. difficile isolates studied was 724. As
we conducted the PCR assay for tcdA and tcdB retro-
spectively, the number of strains available was only 30 in
2000, but the number was increased to 285 in 2005. The
prevalences of tcdA+tcdB+ and tcdA2tcdB+ C. difficile
strains were 93.3 and 6.7% in 2000. No tcdA2tcdB2 C.
difficile strain was detected in that year. However, the
prevalence of the tcdA+tcdB+ strain showed a tendency
toward decrease from 2001 (73.8%) and fell to its lowest
level in 2004, as low as 35.2%. In 2005, the mean
prevalence of tcdA+tcdB+ C. difficile was 47.7%, ranging
from 30.9 to 60.3%. The prevalence of the tcdA2tcdB+
strain began to increase, up to 13.2% in 2003, and finally
up to 50.3% in 2004. In 2005, the mean prevalence of the
tcdA2tcdB+ strains was 27.0%, ranging from 17.6 to
54.8%. The tcdA2tcdB+ variant strains appeared to
become endemic nationwide beginning in 2005. The mean
prevalence of tcdA2tcdB2 C. difficile strains was approxi-
mately 22.4% for 6 years, ranging from 0% (2000) to
32.9% (2003).
Although the mean prevalences of the tcdA+tcdB+ and
tcdA2tcdB+ C. difficile strains over the 6 years were 51.8%
(range 33.3–69.9%) and 25.8% (range 10–56%), the
distributions of tcdA+tcdB+ and tcdA2tcdB+ C. difficile
strains differed from hospital to hospital and from year to
year (Fig. 2). In 2000, the C. difficile strains were collected
only from one hospital (hospital A) and the prevalence of
the variant strain in that hospital was 6.7%. In 2001,
isolates of C. difficile were acquired from two hospitals
(hospitals A and B). However, the variant strains were not
observed in the participating hospital in 2000, although the
mean prevalence of the variant strain was 5%. In 2002, the
rate of prevalence of the variant strain was 4.2% (hospital
A) and 6.0% (hospital B), respectively. In 2003, the
prevalence of the variant strains began to increase up to
16.7% in one hospital, whereas it remained 7.1% in the
other participating hospital. In 2004, another two hospitals
newly participated in the surveillance (hospitals C and D),
and one hospital (hospital B) did not participate in the
follow-up. One of them (hospital D) reported that the
prevalence of tcdA2tcdB+ C. difficile remained less than
7% (6.4%), but the other hospital (hospital C) reported
highly prevalent tcdA2tcdB+ C. difficile strains (71.8%),
suggesting an outbreak. The other continuing participating
hospital (hospital A) reported an increased prevalence of
tcdA2tcdB+ strains (36.4%), which was also suggestive of
outbreak.
In 2005, another two hospitals (hospitals E and F) joined
the surveillance, and they already had highly prevalent
tcdA2tcdB+ strains (25.6 and 54.8%, respectively). Their
tcdA+tcdB+ and tcdA2tcdB2 C. difficile rates were 53.9/
20.5% (hospital E) and 30.9%/14.3% (hospital F),
respectively.
DISCUSSION
TcdA2TcdB+ C. difficile has been reported in several
countries, with varying prevalence rates. As highly
prevalent tcdA2 variant strains were previously isolated
from patients with CDAD in a tertiary hospital in Korea
(Shin & Kuak, 2006; Shin et al., 2008), further nationwide
surveillance was required in order to sufficiently ascertain
the prevalence and virulence of tcdA2tcdB+ strains of C.
difficile in Korea. As published studies revealed no
tcdA2tcdB+ strains among C. difficile isolates in Korea
(Kato et al., 1998; Rupnik et al., 2003) or lower prevalence
rates (4.3%) of these strains (Chung et al., 2002), we
needed to determine at what time these C. difficile strains
became prevalent and truly widely spread throughout
Korea. This study is believed to be the first nationwide
surveillance of C. difficile isolates from patients suspected
of having CDAD in Korea.
We retrospectively obtained 724 C. difficile strains stored in
each of 6 hospitals over 6 years, from 2000 to 2005. The
mean prevalence of tcdA2tcdB+ strains was less than 10%
(range 5.5–6.7%) until 2002, but it almost doubled
(13.2%) in 2003 and reached a maximum at 2004, with
levels as high as 50.3%. The mean prevalence of
tcdA2tcdB+ strains in 2005 was 27.0% (range 17.6–
54.8%), which was approximately four times higher than
was reported in 2000.
The prevalence rates of TcdA2TcdB+ strains were reported
to be 1.3–2% in the USA (Lyerly et al., 1998; Geric et al.,
2004) and 2.7% in France (Barbut et al., 2002). In the UK,
it was estimated that approximately 3% of toxigenic C.
difficile are TcdA2TcdB+ strains (Brazier et al., 1999). It
was identified in 11% of CDAD cases in Poland (Pituch
et al., 2001). A recent 2 month prospective study in Europe
in 2005 showed that 24.3% of C. difficile isolates were toxin
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Fig. 2. The annual prevalence rate of tcdA+tcdB+, tcdA”tcdB+
and tcdA”tcdB” C. difficile strains in each participating hospital
from 2000 to 2005. White bars, prevalence rate (%) of
tcdA+tcdB+ C. difficile strain in each hospital; grey bars,
prevalence rate (%) of tcdA”tcdB+ C. difficile strains in each
hospital; & mean prevalence rate (%) of tcdA+tcdB+ C. difficile
strains in all participating hospitals; m mean prevalence rate (%) of
tcdA”tcdB+ C. difficile strains in all participating hospitals; *,
number of strains tested for each year.
Prevalence of toxigenic C. difficile in Korea
http://jmm.sgmjournals.org 699
variants, and the prevalence rate of toxinotype VIII was 5%
overall among them (Barbut et al., 2007). By way of
contrast, they reported that PCR ribotype 017 was
particularly predominant in Poland, Ireland, Greece and
Sweden, and all PCR ribotype 017 isolates belonged to
toxinotype VIII and were tcdA2tcdB+ strains. Other recent
studies reported that tcdA2tcdB+ strains accounted for
56% in Israel and 44% in Ireland (Samra et al., 2002;
Drudy et al., 2007).
As compared with these reports, the prevalence of
tcdA2tcdB+ strains in Korea was less than or similar to
that of the other countries until 200222003, but has
increased since 2004. Our results revealed that outbreaks of
tcdA2tcdB+ strains were experienced in two hospitals in
2004; infection with these strains remained highly prevalent
in 2005, as compared with published reports in Korea
(Shin & Kim,1992; Lee & Chung, 1993; Lee et al., 1999;
Kang et al., 2000; Chung et al., 2002). One hospital
(hospital F), which was involved only in 2005, is located
450 km from other participating hospitals. However, the
prevalence of tcdA2tcdB+ strains in that hospital had
already reached a level of 56%. The prevalence of variant
strains in Japan was reported to be 12.5% (Kato et al.,
1998). However, variant prevalence rates as high as 39%
during a 1 year period (December 1999–November 2000)
have been reported in CDAD patients, although this was a
report issued by a Japanese hospital (Komatsu et al., 2003).
These results suggested that tcdA2tcdB+ strains had spread
throughout Far East Asia, including Korea and Japan,
before 2000, and these tcdA2tcdB+ strains appeared to be
endemic in many Korean hospitals since 2004.
We are not currently precisely certain as to why we had
such highly prevalent tcdA2tcdB+ strains in Korea over
such a brief duration of time. We surmised that one reason
might be that patients are constantly on the move seeking
better medical service, and C. difficile is a pathogen that is
quite difficult to eradicate, because of its ability to
sporulate (McFarland et al., 1989). Another factor may
be a failure of infection control due to the lack of awareness
of the physicians involved. It appears likely that, at some
point, there must have been a clinical sign of a C. difficile
variant. However, we may have missed this because we did
not possess adequate data regarding the nationwide
prevalence of C. difficile variants prior to 2005, because
culturing, C. difficile is a strenuous procedure in the
majority of laboratories, and EIAs for TcdA only have been
widely utilized for the diagnosis of C. difficile infection in
Korea, as has been reported in other European countries
(Barbut et al., 2003). These commercial toxin A EIAs are
not capable of detecting tcdA2tcdB+ variants, as variant
strains of C. difficile that harbour deletions of 1.7–1.8 kb in
tcdA yielded no detectable TcdA (Kato et al., 1998; Von
Eichel-Streiber et al., 1999; Rupnik et al., 1997). Therefore,
no attention appeared to be paid previously to infection
control, especially with regard to tcdA2tcdB+ C. difficile
strains. Another factor to be considered is that the
diagnostic algorithms of CDAD differ from hospital to
hospital. Therefore, these outbreaks appear to be associated
with delays in CDAD diagnosis in certain hospitals. All of
these factors may result in a significant burden on the
health-care system associated with CDAD (Riley et al.,
1995).
In conclusion, this nationwide epidemiological study
showed that tcdA2tcdB+ C. difficile strains have already
spread widely in Korea, and EIAs capable of detecting both
TcdA and TcdB should be utilized in microbiology
laboratories in order to control these strains of C. difficile
in Korea.
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